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a  b  s  t  r  a  c  t
Objectives:  Pleomorphic  carcinoma  (PC)  of  the  lung is  a rare  epithelial  tumor.  The  clinicopathological
characteristics  and  prognostic  factors  of PC are  controversial.  The  information  on  the  ZEB1  gene,  which
crucially  impacts  survival  of  patients  with  other  malignant  tumors,  is  limited  for  PC.
Materials  and  methods:  Clinicopathological  characteristics  of  62  patients  with  PC were  investigated  in
this  study.  Associations  between  immunohistochemical  expression  of  ZEB1  and  clinical  factors,  including
patient  prognosis,  were  examined.  The  patient  population  consisted  of 51  (82.2%)  men  and  11 (17.8%)
women,  with  a mean  age  of  65.5  years  (range,  31–81  years).
Results:  The  overall  survival  rate  of  the  42  patients,  for whom  follow-up  was  available,  was  68.3%  at  5  years.
Using  TNM  criteria,  7 (11.3%),  11  (17.7%),  3  (4.8%),  21 (33.8%),  15 (24.2%),  2 (3.2%),  and  3  (4.8%)  patients
were  classiﬁed  under  pathological  stage IA, IB, IIA,  IIB, IIIA,  IIIB  and  IV carcinomas,  respectively.  Fifteen
(24.1%)  patients  had  tumors  consisting  entirely  of  spindle  and  giant  cells  (PC  component).  The  other
47  (75.8%)  cancers  contained  additional  carcinoma  components  (i.e., adenocarcinoma  (34/62,  54.8%),
squamous  cell  carcinoma  (7/62,  11.3%),  adenosquamous  carcinoma  (4/62,  6.5%)  and  large  cell carcinoma
(2/62, 3.2%)).  Four  of  7 (57.1%)  stage  IA  (<20 mm)  tumors  consisted  only  of spindle  and  giant cells.  ZEB1
expression  was  observed  only  in  the PC  component.  Diffuse  expression  of ZEB1,  was deﬁned  as positive
nuclear  staining  in  ≥75%  of  cancer  cells,  and  was found  in the  PC component  in  12 patients.  Multivariate
analysis  revealed  that  lymph  node  metastasis,  pleural  invasion,  and  diffuse  ZEB1  expression  in the  PC
component  predicted  poorer  disease-speciﬁc  survival  (p  = 0.007,  0.022,  and  0.016,  respectively).
Conclusion:  This  is  the ﬁrst report  to  indicate  that  ZEB1  may  be  used  as an  immunohistochemical
prognosticator  of  PC,  which  may  be  useful  for  histological  assessment  of  PC  in  biopsy  and  surgical
specimens.
©  2014  Elsevier  Ireland  Ltd.  All  rights  reserved.. Introduction
According to the World Health Organization (WHO) classiﬁca-
ion of lung tumors, pleomorphic carcinoma (PC) is one of ﬁve
ubgroups of sarcomatoid carcinomas [1]. PC is deﬁned as a group
f poorly differentiated non-small cell lung carcinomas (NSCLCs;
Abbreviations: WHO, World Health Organization; PC, pleomorphic carcinoma;
SCLC, non-small cell lung carcinoma; EMT, epithelial–mesenchymal transition;
NM, tumor-node-metastasis; EGFR, epidermal growth factor receptor.
∗ Corresponding author at: Department of Pathology, Fukuoka University School
f  Medicine and Hospital, 7-45-1 Nanakuma, Jonan-ku, Fukuoka city, Fukuoka 814-
180, Japan. Tel.: +81 92 801 1011; fax: +81 92 863 8383.
E-mail address: kaznabes@fukuoka-u.ac.jp (K. Nabeshima).
ttp://dx.doi.org/10.1016/j.lungcan.2014.11.007
169-5002/© 2014 Elsevier Ireland Ltd. All rights reserved.e.g., adenocarcinoma, squamous cell carcinoma, and large cell car-
cinoma), which contain spindle and/or giant cells, or carcinomas
consisting only of spindle or giant cells. The pleomorphic compo-
nent (PC component) should comprise at least 10% of the neoplasm.
The reported values for incidence of PCs have ranged from 0.8%
to 2.1% of all lung carcinomas [2–4]. Patients with PC are usually
diagnosed at a more advanced stage of disease progression, and
experience a more aggressive clinical course of treatment, com-
pared with other NSCLCs [2]. Patient with PC generally have a poor
response to systemic chemotherapy [4]. However, due to its rarity,
no consensus exists on the clinical effects of the clinicopathological
characteristics on the prognosis for patients with PC.
Epithelial–mesenchymal transition (EMT)-related transcrip-
tional factors are increasingly recognized as important contributors
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f these transcriptional factors has a negative effect on patient
urvival. Expression of ZEB family members correlates with
he aggressive phenotype in various other malignancies [8–11].
xpression is associated with more mesenchymal and invasive
roperties in cancer cell lines, and invasive and metastatic proper-
ies and poorer clinical prognosis in primary carcinomas. The ZEB
amily of transcriptional factors has an important role in develop-
ental processes such as gastrulation, neural crest formation, heart
orphogenesis, and formation of the musculoskeletal system and
raniofacial structures. In cancer cells, the functions of the ZEB fam-
ly members are to control cell cycle progression, apoptosis, and
enescence, and to induce the epithelial dedifferentiation leading
o cancer progression [12,13].
We  retrospectively evaluated the clinical and histological fea-
ures of PC in a patient population from a single institution. We  also
sed immunohistochemical staining to investigate the expression
f transcriptional factors (ZEB1), and analyzed associations with
linicopathological parameters. This report is the ﬁrst to show that
igh expression of ZEB1 is an independent and signiﬁcant negative
rognostic factor in PC patients.
. Materials and methods
.1. Patients
Sixty-two cases of PC were detected from a review of 2328
ases of resected tumors in the lung cancer ﬁle of the Depart-
ent of Pathology, Fukuoka University Hospital (Fukuoka, Japan).
he tumors were obtained from surgeries performed between
anuary 1988 and October 2011 at the Department of General
horacic Surgery, Fukuoka University Hospital. The study protocol
as approved by the Ethics Committee of the Fukuoka University
chool of Medicine. Anonymous use of redundant tissue is part of
he standard treatment agreement with patients in our hospitals
hen no objection has been expressed. The pathological stage was
etermined using the tumor-node-metastasis (TNM) classiﬁcation
riteria for malignant tumors (International Union Against Cancer)
14]. The stage IIIB cases were upgraded after surgery because of
he pathological diagnoses of nodal metastasis. For stage IV cases,
artial resections of the primary lung tumor were performed for
istological diagnosis to treat brain metastases.
.2. Pathologic evaluation
The tumors were classiﬁed according to the criteria of the
urrent WHO  histologic classiﬁcation scheme [1]. The coexisting
arcinoma components of each PC were further classiﬁed as
denocarcinoma, squamous cell carcinoma, adenosquamous cell
arcinoma, or large cell carcinoma. The PC components were
ubclassiﬁed as predominantly spindle cell carcinoma or predom-
nantly giant cell carcinoma. The clinicopathological parameters
hat were considered in this study were age, gender, tumor size,
ymph node metastasis, pleural invasion, lymphatic permeation,
nd vascular involvement.
.3. Immunohistochemistry
The surgically resected specimens were ﬁxed in 10% for-
alin, and processed in parafﬁn blocks. Tissue sections (4 m)
ere deparafﬁnized and immersed in 0.3% hydrogen peroxide in
ethanol for 15 min  at room temperature to block endogenous
eroxidase activity. They were then heated in 10 mM citrated
uffer (pH 6.0) in a microwave oven (700 W)  for 10–15 min  to
etrieve epitopes. The sections were incubated with polyclonal
ntibodies against ZEB1 (1:500 dilution; Novus, Littleton, CO)
vernight at 4 ◦C. The sections were then washed and incubatedcer 87 (2015) 39–44
with Dako ChemMate EnVision (Dako, Carpinteria, CA) for ZEB1
Immunoreactive proteins were visualized using diaminobenzidine
(Dako, Carpinteria, CA), followed by counterstaining with hema-
toxylin. Immunohistochemical staining of ZEB1 was  divided into
ﬁve groups; group 1: 0%, group 2: 1–24%, group 3: 25–49%, group
4: 50–74%, and group 5: 75–100%, and then classiﬁed as a diffuse
expression group if ≥75% cancer cells exhibited nuclear staining, or,
as a focal expression group if <75% of the cancer cells were stained.
Most tumors of the focal group showed ZEB1 positivity in up to
50–60% of cells, and therefore diffuse (≥75%) group were selected
easily.
2.4. Statistical analysis
All statistical analyses were performed using StatMate IV for
Windows (ATMS, Tokyo, Japan). The relationships between clini-
copathological parameters and histopathological subgroups were
evaluated using the Chi-square and Fisher’s exact tests. Survival
was analyzed for the 42 patients, because 20 of the 62 patients
were excluded from the analysis. These excuded patients who (1)
did not have radical surgery, (2) died of causes other than lung
cancer, or (3) died within 30 days after surgery. Patient survival
time was calculated from the date of surgery until the date the
ﬁrst recurrence was  diagnosed (relapse-free survival) or until death
from cancer (disease-speciﬁc survival). The Kaplan–Meier method
was used for survival curve analysis, and differences between sur-
vival curves were analyzed using the log-rank test. A univariate
analysis was performed for each clinicopathological parameter.
Multivariate regression analysis and the Cox proportional-hazard
model were used to determine the independent prognostic fac-
tors. A p-value less than 0.05 was considered to be statistically
signiﬁcant.
3. Results
3.1. Clinical and histopathological ﬁndings
Table 1 presents the results for the clinicopathological char-
acteristics of the patients. A total of 62 patients (51 male and 11
female; male to female ratio, 4.6:1) were included in the study. Age
at the time of diagnosis ranged from 31 to 81 years, with a mean
age of 65.5 years. Lobectomy was performed in 55 patients (88.7%),
pneumonectomy in 6 patients (9.7%), and a combination of bilobec-
tomy, segmentectomy, and partial resection was performed for 1
patient (1.6%). Regional lymph node dissection was  performed in
55 patients, and lymph node metastasis was found in 15 patients
(27.3%). Ten of these 15 patients had metastasis with coexisting
carcinoma components (9 adenocarcinoma and 1 squamous cell
carcinoma). The other ﬁve cases included three cases with spindle
cells and two  cases with giant cells. Nodal status was classiﬁed as
pN0 in 40 (64.5%) cases, pN1 in 2 (3.2%) cases, pN2 in 12 (19.4%)
cases, and pN3 in 1 (1.6%) case. The TMN  pathological stages of
PC were classiﬁed as: 7 (11.3%) cases with stage IA, 11 (17.7%) with
stage IB, 3 (4.8%) with stage IIA, 21 (33.8%) with stage IIB, 15 (24.2%)
with stage IIIA, 2 (3.2%) with stage IIIB, and 3 (4.8%) with stage
IV carcinoma. The coexisting carcinoma component ranged from
0% to 90% of the whole tumor area and consisted of adenocarci-
noma in 34 patients (54.8%), squamous cell carcinoma in 7 patients
(11.3%), adenosquamous cell carcinoma in 4 patients (6.5%), and
large cell carcinoma in 2 patients (3.2%). Fifteen patients (24.2%) had
no coexisting carcinoma component. The PC component accounted
for 10–100% of tumor volume, and was spindle cell in 18 patients
(29.0%), giant cell in 7 patients (11.3%), and was  mixed, in the
remaining 37 patients (59.7%).
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Table  1
Clinicopathological characteristics (N = 62).




























Squamous cell carcinoma 7 (11.3)
Adenosquamous cell carcinoma 4 (6.5)



















Results of univariate analysis of prognostic factors affecting disease-speciﬁc and







Tumor size 0.25 0.52
p-N positive 0.037* 0.042*
Pleural invasion 0.031* 0.014*
Lymphatic permeation 0.16 0.075
Vascular involvement 0.93 0.97
Necrosis 0.89 0.92
ZEB1, diffuse expression 0.034* 0.031*





Spindle cell 42 (67.7)
Giant cell 20 (32.3)
The coexisting carcinoma portions occurred more frequently in
arger PCs. The mean percentages of coexisting carcinoma portions
n the entire tumor were 8.5% in tumors ≤20 mm,  26.9% in tumors
20 mm and ≤50 mm,  and 23.7% in tumors >50 mm.  There were
even cases of p-T1a cancer (≤20 mm diameter, mean 16.1 mm,
ange 10–20 mm)  (Table 2). Three (42.9%) of the seven cases had
 coexisting carcinoma component, one was an adenocarcinoma
omponent and two squamous cell carcinoma component. They
ccupied approximately 10%, 10%, and 40%, respectively, of each
ntire tumor. Spindle cells were detected as a predominant PC
omponent in all but one case. Ipsilateral recurrence occurred in
ne patient, who died within 1 year after surgery. However, the
ther six patients were alive after 1 year and did not experience
ecurrence. These six patients did not receive chemotherapy or
adiotherapy. The 5-year disease-speciﬁc survival rate of these six
tage IA PC patients (pT1a-size) was 83% (one patient was lost dur-
ng follow-up).
able 2
haracteristics of seven patients with a tumor ≤2 cm diameter.
Age/gender Coexisting carcinoma component Predominant ple
74/M AD (10%) Spindle cell 
66/M None Spindle cell 
59/M SQ (40%) Giant cell 
71/M None Spindle cell 
71/M SQ (10%) Spindle cell 
46/M None Spindle cell 
73/F  None Spindle cell 
D, adenocarcinoma; SQ, squamous cell carcinoma.
By reason of pleural invasion.* Statistically signiﬁcant.
Twenty three patients with adjuvant chemotherapy (p-stage
II or III), those with diffuse ZEB1 expression had signiﬁcantly
shorter overall survival compared with those with focal expression
(p = 0.030, data not shown).
3.2. Immunohistochemical analysis of ZEB1
ZEB1 expression was  detected only in the nuclei of spindle or
giant cells of the PC component (Fig. 1). Diffuse expression of ZEB1
was found in 12 patients (19.4%).
3.3. Patient survival
Fig. 2A and B presents the post-surgery disease-speciﬁc survival
and relapse-free survival curves, respectively, by tumor stage. The
5-year disease-speciﬁc survival rate was  84.6% for stage I, 70.5% for
stage II, and 45.4% for stage III, PC patients. There was a statistically
signiﬁcant difference between survival of stages I and III PC patients
(p = 0.015). The 5-year relapse-free survival rate in stages I, II, III
was 76.9%, 52.9%, and 41.6%, respectively. The difference between
stages I and III (p = 0.021) was  statistically signiﬁcant.
Patients with diffuse expression of ZEB1 had shorter disease-
speciﬁc (p = 0.031) and relapse-free (p = 0.034) survival times
compared with patients with focal expression of ZEB1, and the
differences were statistically signiﬁcant.
Table 3 presents the results for the univariate analysis of clin-
icopathologic predictors of survival in the PC patients. Lymph
node metastasis, pleural invasion, and diffuse expression of ZEB1
predicted poorer relapse-free survival and poorer disease-speciﬁc
survival. The epithelial component or PC component subtypes did
not affect prognosis (data not shown).
A multivariate analysis of patient relapse-free survival revealed
that lymph node metastasis and diffuse expression of ZEB1 were
independent prognostic factors for poor survival (Table 4, upper).
Lymph node metastasis, pleural invasion and diffuse expression of
omorphic component pT (mm) pN Survival
2aa (16) 0 Dead
1a (20) 0 Alive
1a (10) 0 Alive
2aa (15) 0 Alive
1a (17) 0 Alive
1a (15) 0 Alive
1a (20) 0 Alive
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Fig. 1. Expression of ZEB1 in pleomorphic carcinoma (PC). A representative case of













Fig. 2. (A) Kaplan–Meier disease-speciﬁc survival curve for pleomorphic carcinoma,
stratiﬁed by stage at diagnosis (n = 42). The solid line indicates stage I; dash-dotted
line, stage II; broken line, stage III. There was a statistically signiﬁcant difference
between stages I and III (p = 0.015). There were no signiﬁcant differences between
stages I and II, stage II or stage III. (B) Kaplan–Meier relapse-free survival curve for
pleomorphic carcinoma, stratiﬁed by to stage at diagnosis (n = 42). The solid line
indicates stage I; dash-dotted line, stage II; broken line, stage III. There was a sta-
tistically signiﬁcant difference between stages I and III (p = 0.021). The differences
between stages I and II, and between stages II and III, were not statistically signiﬁ-
cant. (C) Kaplan–Meier disease-speciﬁc survival curve for pleomorphic carcinoma,
stratiﬁed according to ZEB1 expression. The dotted line indicates diffuse expression
of  ZEB1; solid line, focal expression of ZEB1. There was a statistically signiﬁcant
difference between the two groups (p = 0.031). (D) Kaplan–Meier relapse-free sur-
vival curve for pleomorphic carcinoma, stratiﬁed by ZEB1 expression. The dotted
line indicates diffuse expression of ZEB1; solid line, focal expression of ZEB1. There
was  a signiﬁcant difference between the two  groups (p = 0.034).
Table 4
Results of multivariate analysis of prognostic factors affecting disease-speciﬁc and
relapse-free survival after surgical resection (N = 42).
Relative risk 95% CI p
Relapse-free survival
p-N positive 3.804 1.366–10.594 0.010*
ZEB1, diffuse expression 3.929 1.423–10.843 0.008*
Pleural invasion 2.083 0.949–4.570 0.067
Tumor Size 0.442 0.092–2.118 0.307
Lymphatic permeation 1.374 0.485–3.890 0.549
Gender 0.442 0.092–2.118 0.307
Disease-speciﬁc survival
p-N positive 4.396 1.487–12.99 0.007*
ZEB1, diffuse expression 3.297 1.244–8.738 0.016*
Pleural invasion 3.134 1.172–8.375 0.022*
Tumor Size 0.935 0.406–2.156 0.876hows the spindle cell component in a PC. Diffuse ZEB1 expression occurred in the
pindle cell nuclei (B), but the adenocarcinoma components were ZEB1-negative
C). (A) HE ×12.5, inset ×400; (B) and (C) ZEB1 immunohistochemistry ×200
EB1 were independent prognostic factors for poor disease-speciﬁc
urvival (Table 4, lower).
. Discussion
We  are the ﬁrst to report that diffuse ZEB1 expression in the
C component (spindle or/and giant cells) was signiﬁcantly associ-
ted with shorter relapse-free and disease-speciﬁc survival in PC
atients. The results of multivariate analysis indicated that dif-
use ZEB1 expression was an independent poor prognostic factor.
ymph node metastasis and pleural invasion were also indepen-
ent poor prognostic factors for relapse-free and disease-speciﬁc
Lymphatic permeation 0.694 0.266–1.808 0.455
Pleomorphic component (≥75%) 0.179 0.023–1.385 0.099
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urvival or disease-speciﬁc survival, respectively. Moreover, an
nalysis of smaller p-T1a size PCs indicated higher percentages
f tumors without a coexisting carcinoma component, and longer
urvival. The 5-year disease-speciﬁc survival rate was 83%.
Several reports have described various relationships between
EB1 expression and clinicopathological parameters for different
ancers. A high expression of ZEB1 is associated with liver metas-
asis and low survival rates in colorectal cancer patients [15]. In
ancreatic cancer patients, a decrease in E-cadherin expression
nd an increase in ZEB1 or ZEB2 expression are associated with
 poorer prognosis and nodal metastasis [8]. Up-regulation of ZEB1
xpression is linked to disruption of cell–cell interactions that lead
o cancer cell migration and invasion in patients with malignant
ndometrial cancer [16]. One of the well-known functions of ZEB1
n cancer cells is to cause down-regulation of E-cadherin, which
s a hallmark of EMT, the generation of motile mesenchymal cells
rom epithelial sheets. In this study, we investigated the expression
f E-cadherin in PC and in coexisting carcinoma components (data
ot shown). E-cadherin immunoreactivity was variably observed in
ormal epithelium and the coexisting carcinoma component, but
as completely absent in the PC component in all cases, irrespec-
ive of the varying degrees of ZEB1 expression. Thus, there was no
nverse correlation between expression levels of E-cadherin and
EB1 within the PC component.
Recently, ZEB1 functions that are unrelated to EMT  have been
eported. The non-EMT functions include regulation of cell cycle
rogression, apoptosis and senescence [12]. ZEB1 directly binds
o the promoters of genes encoding cyclin-dependent kinase
nhibitors (e.g., p21, p27 and p57) to control the cell cycle [17].
EB1 also interferes with a complex regulatory network of p53
amily members and their targets to support either pro-survival
r proapoptotic responses [12]. Furthermore, ZEB1 appears to be a
actor that override drug resistance and oncogene addiction. Silenc-
ng ZEB1 using siRNA restores cell sensitivity to DNA damaging
gents, such as gemcitabine, 5-ﬂuorouracil (5-FU), and cisplatin
18]. Moreover, ZEB1 depletion sensitizes head and neck squa-
ous cell carcinoma cells to the epidermal growth factor receptor
EGFR) inhibitor, erlotinib [12,19]. In our study, the prognosis did
ot signiﬁcantly different between the patients who received adju-
ant chemotherapy or not. However, diffuse expression of ZEB1
igniﬁcantly correlated with poor prognosis compared with focal
xpression in the 23 patients with adjuvant chemotherapy. This
esult has the possibility of predictive factor of response against
djuvant chemotherapy. However, further studies are required to
nvestigate the biological functions of ZEB1 in PCs in this point.
iffuse ZEB1 expression was not signiﬁcantly correlated with
linicopathological parameters such as size, presence of necrosis,
ymphovascular involvement, pleural invasion, and predominant
leomorphic or coexisting carcinoma components. The precise
echanisms via which ZEB1 expression affected PC patient sur-
ival remain to be elucidated, but the previously mentioned EMT
nd non-EMT-related mechanisms may  both be involved.
The contributions of unfavorable clinicopathological factors,
uch as nodal involvement [20,21], no surgery [3,4], higher patho-
ogic stages [22,23], and pleural invasion [24] have been reported.
assive coagulation necrosis and lymphatic permeation are also
ndependent prognostic factors that predict a poor outcome [2].
he results of our study indicated that lymph node metastasis and
leural invasion were independent prognostic factors for disease-
peciﬁc survival of PC patients. However, the type of coexisting
arcinoma and the PC component did not affect prognosis (data
ot shown). The percentage of PC component in the entire tumor
id not affect prognosis in early-stage or in advanced-stage tumors.
s favorable prognostic factors, it is reported that lymphoplasma-
ytic inﬁltration in the marginal stroma and lymph follicles around
umors, which were found in stages I and II, were associated withcer 87 (2015) 39–44 43
favorable prognosis in giant cell carcinomas [25]. In our study, there
was no association of the peritumoral lymphoplasmacytic inﬁltra-
tion and lymph follicle formation with good survival of pT1a PCs.
The prevalent hypothesis for the origin of the PC component
is epithelial derivation with divergent mesenchymal dedifferenti-
ation, so-called EMT, but it has not been well-deﬁned [2,26,27].
Consistent with this view, we hypothesized that the coexisting
adeno-, squamous, and large cell carcinoma portions are larger in
smaller PCs, and become relatively smaller as the tumor increases
in size. However, the results of our study revealed that only 3
(43%) of 7 p-T1a size (≤20 mm in greatest dimension) tumors
contained coexisting carcinoma portions, whereas the coexisting
carcinoma portions were found in 23 (88.5%) of 26 tumors >20 mm
and ≤50 mm in the greatest dimension, and in 19 (65.5%) of 29
tumors >50 mm in greatest dimension. Contrary to our hypothe-
sis, the frequency and mean percentage of coexisting carcinoma
portion were increased along to the entire tumor size. Furthermore,
it was  recently reported that the EGFR mutation was  found in 3
(18%) of 17 patients with PC; these mutations were detected in the
adenocarcinomatous component, but not in the pleomorphic com-
ponent [4]. These ﬁndings suggest the possibility of a common stem
cell or an independent multiclonal origin for pleomorphic and coex-
isting carcinoma components rather than an EMT-based derivation
of the PC component from coexisting carcinomas.
In conclusion, we found that diffuse ZEB1 expression an
immunohistochemical prognosticator in PC patients. Further inves-
tigation will be required to elucidate the mechanisms whereby
ZEB1 expression leads to a poor prognosis. These results suggest
that the ZEB1 gene may  be useful as a new molecular target for
therapy for patients with PC.
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